Abstract
Cardiovascular causes belong among the most common causes of mortality and morbidity in our country. Over the past 30 years, there has been significant regression in their number, but they are still the leading cause of mortality.
Targeted and consistent intervention of atherosclerosis risk factors significantly contributes to this decline. Atherosclerosis is a dynamic process and antiaggregation therapy is clearly indicated at its clinical manifestation in form of cardiovascular events.
There fore, administration of antiaggregation therapy in primary prevention was expected to prevent manifestation or reduction of CVD amount. This fact has been proved eg. especially in the case of coronary events, however, there was an increased manifestation of adverse events, predominantly in the form of gastrointestinal bleeding and cerebrovascular bleeding, and overall mortality or morbidity was unaffected.